Abstract Number: 2144 • ACR Convergence 2023
Pharmacodynamic Effects of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): Results from the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2A IRIS-RA Study
Background/Purpose: Nipocalimab is a fully human, immunoglobulin G (IgG) 1 monoclonal antibody that blocks the neonatal crystallizable fragment receptor (FcRn), thereby lowering IgG levels. RA…Abstract Number: 2232 • ACR Convergence 2023
Guselkumab, an IL-23p19 Subunit–specific Monoclonal Antibody, Is Able to Bind CD64+ Myeloid Cells, Potently Neutralize IL-23 Produced from the Cells, and Mediate Internalization of IL-23
Background/Purpose: Monoclonal antibodies (mAbs) targeting the interleukin (IL)-23p19 subunit are effective in treating psoriatic disease; however, their molecular attributes may translate to differences in clinical…Abstract Number: 2030 • ACR Convergence 2022
Designing of a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Inhibitor, in Adults with Primary Sjögren’s Syndrome
Background/Purpose: Dysregulated humoral immunity is a hallmark of primary Sjögren's Syndrome (pSS). This dysregulation involves aberrant B-lymphocyte activity resulting in abnormally high immunoglobulin G (IgG)…Abstract Number: 1854 • ACR Convergence 2022
Nipocalimab’s Selective Targeting of FcRn and IgG Clearance Preserves Key Immune Functions
Background/Purpose: Nipocalimab, a fully human, effectorless IgG1 anti-neonatal Fc receptor (FcRn) monoclonal antibody, binds to FcRn with high affinity which prevents IgG recycling, leading to…Abstract Number: 0044 • ACR Convergence 2021
Autoantibodies Against Malondialdehyde-modifications Promote Osteoclast Development by Reprogramming Cellular Metabolism
Background/Purpose: Malondialdehyde (MDA) is a highly reactive compound generated during lipid-peroxidation in conditions associated with oxidative stress. MDA can irreversibly modify proteins (e.g. lysine, arginine…Abstract Number: 0973 • ACR Convergence 2021
Modeling of Clinical Phenotypes in SLE Based on Platelet Transcriptomic Analysis and FCGR2a Biallelic Variants
Background/Purpose: The clinical heterogeneity of SLE with its complex pathogenesis remains challenging as we strive to provide optimal management. The contribution of platelets to endovascular…Abstract Number: L14 • 2018 ACR/ARHP Annual Meeting
Top-Line Results of a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE)
Background/Purpose: XmAb5871 is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcgRIIb. Co-ligation of CD19 and FcgRIIb inhibits B lineage cells key to SLE…Abstract Number: 1986 • 2018 ACR/ARHP Annual Meeting
Adalimumab:TNF Complexes Are Cleared More Efficiently By Human Osteoclasts Than Those with Etanercept through Fcg-Receptor Binding and Internalization
Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis (OCgenesis) independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast…Abstract Number: 2037 • 2018 ACR/ARHP Annual Meeting
CTLA4 Signaling Down-Regulates Fcγ Receptor I Expression on Circulating Monocytes: A Potential Mechanism of Action of Abatacept for RA
Background/Purpose: Abatacept is a recombinant fusion protein comprising cytotoxic T lymphocyte antigen 4 (CTLA4) and Fc region of immunoglobulin (Ig), which is efficacious against rheumatoid…Abstract Number: 59 • 2016 ACR/ARHP Annual Meeting
Novel Agents for Blocking the Interaction of Immune Complexes with the Activatory FcγRIIIa Receptor
Background/Purpose: Protein-protein interactions are essential for the control of cellular functions and critical for regulation of the immune system. One example is the binding of…Abstract Number: 1006 • 2016 ACR/ARHP Annual Meeting
Immune Complex-Mediated TLR8 Activation Shifts Neutrophils from Phagocytosis to Netosis through Furin-Dependent Shedding of Fcgriia
Background/Purpose: Neutrophils, isolated from healthy individuals, were incubated with RNA-ICs and analyzed for phagocytosis and NETosis by flow cytometry and fluorimetry, respectively, in the presence…Abstract Number: 1569 • 2016 ACR/ARHP Annual Meeting
Increased Circulating CD14brightCD16+ Intermediate Monocytes Are Regulated By Interleukin-10 in Patients with Rheumatoid Arthritis
Background/Purpose: The study enrolled 35 untreated RA patients and 14 healthy volunteers. DAS28-ESR was evaluated and peripheral blood samples were obtained at baseline and following…Abstract Number: 2065 • 2016 ACR/ARHP Annual Meeting
Platelet FcγRIIa Polymorphism H131R Associates with Subclinical Atherosclerosis and Increased Platelet Activity in SLE
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by heterogeneity of presentation, an undulating course, and elevated risk for premature cardiovascular disease.…Abstract Number: 2263 • 2016 ACR/ARHP Annual Meeting
Apolipoprotein E Regulates Inflammation and Joint Destruction during Antigen-Induced Arthritis (AIA)
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease largely driven by immune complexes and their interaction with FcγRs present on macrophages within the synovium.…Abstract Number: 543 • 2015 ACR/ARHP Annual Meeting
The IL-20 Receptor Axis in Early Rheumatoid Arthritis: Novel Inflammation-Independent Links Between Autoantibody Positivity and Radiographic Progression
Background/Purpose: Rheumatoid arthritis (RA) is often characterized by the presence of rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPAs) and bone erosions. Successful treatment can compromise…
ACR Meeting Abstracts